Evaluation of interplay and organ motion effects by means of 4D dose reconstruction and accumulation

• Published in: Radiotherapy and oncology 2020-09, Vol.150, p.268-274
• Main Authors: Meijers, Arturs, Knopf, Antje-Christin, Crijns, Anne P.G., Ubbels, Jan F., Niezink, Anne G.H., Langendijk, Johannes A., Wijsman, Robin, Both, Stefan
• Format: Article
• Language: English
• Subjects: 4D dose reconstruction; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - radiotherapy; Four-Dimensional Computed Tomography; Humans; Interplay; Lung Neoplasms - radiotherapy; Movement; Organ Motion; Pencil beam scanning; Proton Therapy; Radiotherapy Planning, Computer-Assisted; Thoracic cancer
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2020.07.055

•4D dose reconstruction and accumulation has been applied in clinical practice.•No relevant loss of target dose homogeneity due to interplay was observed.•Anatomical changes showed more pronounced effect on target dose than interplay. Pencil beam scanned proton therapy (PBS-PT) treatment quality might be compromised by interplay and motion effects. Via fraction-wise reconstruction of 4D dose distributions and dose accumulation, we assess the clinical relevance of motion related target dose degradation in thoracic cancer patients. For the ten thoracic patients (Hodgkin lymphoma and non-small cell lung cancer) treated at our proton therapy facility, daily breathing pattern records, treatment delivery log-files and weekly repeated 4DCTs were collected. Patients exhibited point-max target motion of up to 20 mm. They received robustly optimized treatment plans, delivered with five-times rescanning in fractionated regimen. Treatment delivery records were used to reconstruct 4D dose distributions and the accumulated treatment course dose per patient. Fraction-wise target dose degradations were analyzed and the accumulated treatment course dose, representing an estimation of the delivered dose, was compared with the prescribed dose. No clinically relevant loss of target dose homogeneity was found in the fraction-wise reconstructed 4D dose distributions. Overall, in 97% of all reconstructed fraction doses, D98 remained within 5% from the prescription dose. The V95 of accumulated treatment course doses was higher than 99.7% for all ten patients. 4D dose reconstruction and accumulation enables the clinical estimation of actual exhibited interplay and motion effects. In the patients considered here, the loss of homogeneity caused by interplay and organ motion did not show systematic pattern and smeared out throughout the course of fractionated PBS-PT treatment. Dose degradation due to anatomical changes showed to be more severe and triggered treatment adaptations for five patients.